Under the terms of the agreement,
“Over the course of 2015, bluebird has continued to expand its
immuno-oncology research and preclinical programs, building a broad
pipeline of multiple targets in solid and hematologic malignancies. We
are pleased to enter this agreement with
“CAR T technology has been gaining worldwide attention in recent years
as an innovative technology backed by highly promising results from
recent clinical studies,” said
About bluebird bio, Inc.
With its lentiviral-based gene
therapy and gene editing capabilities, bluebird bio has built an
integrated product platform with broad potential application to severe
genetic diseases and T cell-based immunotherapy. bluebird bio’s clinical
programs include Lenti-D™ product candidate currently in a Phase 2/3
study, called the Starbeam Study, for the treatment of childhood
cerebral adrenoleukodystrophy, and LentiGlobin® BB305 product
candidate, currently in three clinical studies: a global Phase 1/2
study, called the Northstar Study, for the treatment of beta-thalassemia
major; a single-center Phase 1/2 study in
bluebird bio has operations in
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
About
bluebird bio Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements regarding the research, development and advancement of
bluebird bio’s product candidates and CAR T research program. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, the risk that bluebird bio’s CAR-T research program for this target
will be unsuccessful and not identify any viable product candidates, the
risk of cessation or delay of any planned clinical studies and/or our
development of our product candidates, and the risk that any one or more
of our product candidates will not be successfully developed and
commercialized. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in our most recent annual report on Form
10-K, as well as discussions of potential risks, uncertainties, and
other important factors in our subsequent filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20151203005370/en/
Source: bluebird bio, Inc.
bluebird bio, Inc.
Investors and Media:
Manisha
Pai, 617-245-2107
mpai@bluebirdbio.com
or
Media:
Pure
Communications, Inc.
Dan Budwick, 973-271-6085
or
ViroMed
Co., Ltd.
Investors Relations:
Suyoung Go, +82-2-2102-7212
sindy1524@viromed.co.kr
or
Kenneth
Song, +82-2-2102-7227
jgsong@viromed.co.kr